Disease related indicators for a proper choice of adjuvant treatments

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast Cancer; Prediction; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHEMOSENSITIVITY; EVIDENCE BASED MEDICINE; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; PATHOLOGICAL ANATOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TUMOR VOLUME;

EID: 80054848795     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70317-4     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May, 365(9472):1687-1717.
2. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009 Jan, 11(l):3-14.
3. Sargent DJ, Conley BA, Allegra C, Collette L Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005 Mar 20, 23(9):2020-2027.
4. Simon RM, Paik S, Hayes DF Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009 Nov 4, 101(21):1446-1452.
5. Hayes DF, Trock B, Harris A Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?. Breast Cancer Res Treat 1998, 52:305-319.
6. AJCC Breast. AJCC Staging Manual 2010, Springer, New York. 7th edn. S.B. Edge, D.R. Byrd, C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N EnglJ Med 2004, 351:2817-2826.
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J C/in. Oncol 2007 Jan l, 25(l):118-145.
9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010 Jul, 134(7):e48-e72.
10. Paik S, Kim C, Wolmark N HER2 status and benefit from adjuvant trastuzumab in breast cancer. N EnglJ Med 2008 Mar 27, 358(13):1409-1411.
11. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010 Oct 1, 28(28):4307-4315.
12. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad SciUSA 1999, 96(16):9212-9217.
13. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
14. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad SciUSA 2001 Sep 11, 98(19):10869-10874.
15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin R Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007 Nov 20, 25(33):5287-5312.
16. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 Jun 1, 28(16):2784-2795.
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 Dec 30, 351(27):2817-2826.
18. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 Dec 19, 347(25):1999-2009.
19. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009 Mar 10, 27(8):1160-1167.
20. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010 Apr, 11(4):339-349.
21. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N EnglJ Med 1978, 298:1223-1228.
22. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2008 Mar, 108(2):183-190.
23. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. J Clin Oncol 2006 May 23, 24:3726-3734.
24. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010 Jan, 11(l):55-65.
25. Sparano JA, Paik S Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 Feb 10, 26(5):721-728.